致心律失常性右室心肌病室性心动过速的射频消融治疗

目的评价致心律失常性右室心肌病(ARVC)室性心动过速(VT)射频消融的疗效。方法 4例ARVC患者,男3例,女1例,年龄27～62岁,均有反复头昏、心悸、晕厥或黑矇病史。4例患者症状发作时共出现6种形态的VT,频率为130～210次/分。在三维标测系统(CARTO或EnSite Array)指导下行VT消融治疗。结果 4例患者共行6次手术,其中3次采用CARTO系统,3次采用EnSiteArray系统指导。3例完成消融,随访2～19个月,3例患者均无猝死、晕厥或黑矇发生;2例术后一周内复发,但VT的频率减慢,药物能有效控制,术后5～6个月VT不再发作。另1例患者在放电消融过程中VT的频率加快,形态紊乱,蜕变为心室颤动,紧急电复律后转为窦性心律,终止手术。随访6个月,无VT发生。结论致心律失常性右室心肌病VT的射频消融治疗可改善病人的症状。     

三维标测指导致心律失常性右心室心肌病室性心动过速的射频消融

目的介绍致心律失常性右心室心肌病（ARVC）室性心动过速（室速）的三维标测方法及其消融策略。方法21例ARVC室速患者,因1—4种抗心律失常药物治疗无效,临床上呈反复发作、无休止发作或植入型心律转复除颤器（ICD）植入后频繁放电治疗,接受导管消融治疗。其中,男性19例,女性2例,平均年龄（32±12）岁。9例患者接受电解剖（Carto）标测,12例患者接受非接触标测（EnSite—Array）。在首先明确病变基质的基础上,通过激动标测、拖带标测及起搏标测,分析心动过速的起源、可能的传导径路及其出口以及它们与病变基质的关系。通常于心动过速的出口处及其周边行局灶消融,术中病变基质周边的延迟激动电位应一并消融。结果21例患者,2例呈无休止发作,1例患者表现为频繁室性早搏及加速性室性自主心律,余18例患者消融中共诱发出34种心动过速。所有心动过速均呈左束支阻滞形,平均心动过速周长为（289±68）ms。16例患者（28种室速）消融治疗即刻成功,3例患者（7种室速）部分成功,2例患者（2种室速）消融失败,即刻消融成功率76．2％。所有患者消融术后继续服用抗心律失常药物。平均随访6～30（1d±7）个月,成功患者中2例复发,其中1例再次消融成功;未达即刻成功的5例患者,经抗心律失常药物治疗后,均无室性心律失常事件发生,其中包括1例消融后植入ICD者。结论三维标测系统可首先明确ARVC患者的病变基质,在此基础上结合激动标测和心内各种电刺激技术,可直观显示心动过速的起源、缓慢传导区出口及折返环路,以此制定消融策略可成功治疗ARVC室速。心动过速起源于心肌深部或ARVC病变进展,是消融失败和复发的常见原因。     

Ablation strategies for arrhythmogenic right ventricular cardiomyopathy:a systematic review and meta-analysis

BackgroundCatheter ablation for ventricular tachycardia (VT) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) has significantly evolved over the past decade. However, different ablation strategies showed inconsistency in acute and long-term outcomes.MethodsWe searched the databases of Medline, Embase and Cochrane Library through October 17, 2019 for studies describing the clinical outcomes of VT ablation in ARVC. Data including VT recurrence, all-cause mortality, acute procedural efficacy and major procedural complications were extracted. A meta-analysis with trial sequential analysis was further performed in comparative studies of endo-epicardial versus endocardial-only ablation.ResultsA total of 24 studies with 717 participants were enrolled. The literatures of epicardial ablation were mainly published after 2010 with total ICD implantation of 73.7%, acute efficacy of 89.8%, major complication of 5.2%, follow-up of 28.9 months, VT freedom of 75.3%, all-cause mortality of 1.1% and heart transplantation of 0.6%. Meta-analysis of 10 comparative studies revealed that compared with endocardial-only approach, epicardial ablation significantly decreased VT recurrence (OR: 0.50; 95% CI: 0.30-0.85; P = 0.010), but somehow increased major procedural complications (OR: 4.64; 95% CI: 1.28-16.92; P= 0.02), with not evident improvement of acute efficacy (OR: 2.74; 95% CI: 0.98-7.65; P = 0.051) or all-cause mortality (OR: 0.87; 95% CI: 0.09-8.31; P = 0.90).ConclusionCatheter ablation for VT in ARVC is feasible and effective. Epicardial ablation is associated with better long-term VT freedom, but with more major complications and unremarkable survival or acute efficacy benefit.     

Electrocardiographic (ECG) clues to differentiate idiopathic right ventricular outflow tract tachycardia (RVOTT) from arrhythmogenic right ventricular cardiomyopathy (ARVC)

Introduction

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic cardiomyopathy that most commonly affects young adults. The most commonly observed reason of death in patients suffering from ARVC/D is sudden cardiac death (SCD). On the other hand, idiopathic right ventricular outflow tract tachycardia (RVOT VT) usually has a benign course. Both of the entities may have ventricular tachycardia (VT) with left bundle branch block (LBBB) pattern and inferior axis. We tried to propose new discriminating electrocardiographic indices for differentiation of foretold entities.

Material and method

This was a retrospective study. We reviewed records of patients admitted between 2003 and 2012 with the diagnosis of either ARVC/D or RVOT VT that presented with VT (LBBB morphology).

Result

A total of fifty nine patients (30 RVOT VT and 29 ARVC/D) were enrolled. In ARVC/D group, men were dominant while the reverse was true of RVOT VT. Palpitation was more common in the RVOT VT group (90% vs. 66.7%), but aborted SCD and sustained VT were more common in ARVC/D group. The new ECG criteria proposed by us mean QRS duration in V1–V3, QRS difference in right and left precordial leads, S wave upstroke duration, JT interval dispersion, QRS and JT interval of right to left precordial leads were all significantly longer in ARVC/D when compared to RVOT VT patients (p < 0.001).

Conclusion

The proposed ECG criteria can be used for non-invasive diagnosis of ARVC/D and incorporation in the future updates of ARVC/D task force criteria.     

Macroreentrant ventricular tachycardia mimicking focal ventricular tachycardia in a case with arrhythmogenic right ventricular cardiomyopathy

A 67-year-old man with ventricular tachycardia (VT) due to arrhythmogenic right ventricular cardiomyopathy (ARVC) underwent electrophysiologic testing. Electroanatomic mapping during the VT seemed to reveal a focal mechanism from near the tricuspid annulus (TA). Several radiofrequency applications delivered at the presumed focus resulted in termination but re-induction of the VT. Additional electroanatomic mapping underneath the TA led to the diagnosis of macroreentrant VT. Several RF applications targeting isolated and late potentials observed there during sinus rhythm eliminated the VT. In ARVC cases, detailed mapping underneath the TA should be performed to reveal the VT mechanism, resulting in suppressing VT recurrences. There was no financial support for this study.     

致心律失常性右室心肌病的CARTO系统电生理基质标测和射频导管消融

目的应用CARTO系统对致心律失常性右室心肌病(ARVC)患者进行电解剖标测并指导射频消融治疗其室性心动过速(简称室速)。方法入选伴有室速反复发作的25例ARVC患者,年龄36±12岁,男性17例,有家族成员35岁以下早发猝死史3例。术前行常规心电图、心室晚电位、心脏B超检查。在窦性心律或/和心动过速时,电解剖标测三维重建右室。术中6例同时行右室造影检查。根据双极电图电压高低确定疤痕区、正常心肌和临界边缘区。对于折返性室速,线性消融关键峡部或疤痕区与三尖瓣环之间或两疤痕区间;对于局灶性室速,点消融局部最早激动区域。结果 20%(5/25)体表心电图发现前壁或下壁导联Epsilon波,心室晚电位阳性占88%(21/25),心脏B超发现右室不同程度的局部或整体扩张,56%(14/25)可见局部囊袋状向外膨出。所有患者均出现1～5(2±1)种左束支阻滞型室速,其中5例合并频发室性早搏,1例伴心房扑动,1例伴左后间隔旁道。即时消融成功率为72%(18/25)。随访14±10(4～36)个月,原消融成功的5例室速复发。1例消融失败伴晕厥史的患者植入ICD治疗。无手术相关并发症和死亡发生。结论应用CARTO系统电解剖标测可安全有效指导射频消融治疗ARVC患者的室速,有相对较高的失败和复发率。CARTO系统标测的电压图,参考术前心电图、心脏B超及右室造影可了解病变心肌的分布范围,对初步确定室速的病理基质有帮助。     

Ventricular tachycardia mapping and ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia:Lessons Learned

Arrhythmogenic right ventricular cardiomyopathy/dysplasia(ARVC/D) is primarily believed to be an inherited cardiomyopathy that subsequently results in significant myocardial fibrosis. The arrhythmogenic consequences that result from the development of fibrosis are similar to other nonischemic cardiomyopathies, but the unique endocardial-epicardial disease process of ARVC/D requires a specialized approach for arrhythmia treatment in the electrophysiology laboratory. Although the association between ARVC/D and development of ventricular arrhythmias has become increasingly clear over the last 2 decades, our understanding of the arrhythmia mechanisms, underlying electrophysiologic substrate, and treatment strategies were significantly limited. Prospective studies performed in the electrophysiology laboratory allowed detailed characterization of the electrophysiologic and electroanatomic substrate underlying ventricular tachycardia in patients with ARVC/D. Thishas allowed clinician scientists to better characterize the arrhythmia mechanism and develop the necessary strategies to perform successful catheter ablation. Early in this experience, catheter ablation was considered a limited and largely unsuccessful treatment for patients experiencing painful and recurrent defibrillator therapy. Through our increased understanding of the disease process, catheter ablation has evolved to become an effective and preferred therapy for a majority of these patients. Our understanding of the disease and necessary approaches to provide successful treatment continues to evolve as the clinical experience grows. This article will review these important insights from the electrophysiology laboratory and how application of this knowledge has facilitated the development of a methodical approach to successfully perform ventricular tachycardia ablation in patients with ARVC/D.     

致心律失常性右心室心肌病室性心动过速的导管射频消融

目的致心律失常性右心室心肌病（ARVC）所致的多形室性心动过速（室速）具有较高的死亡风险，心内非接触式标测可提供快速而准确的标测并指导消融。方法32例患者（男性26例，女性6例），年龄（37．2±13．8）岁，其中14例有晕厥／黑矇史，2例已植入心律转复除颤器（ICD）。所有患者均经左锁骨下静脉送入EnSite多电极矩阵导管进行非接触式标测。结果全部患者共诱发出67阵室速，其心电图形态不同，但均为左束支阻滞形室速。频率130～310（210．0±32．2）次／min，其中42阵室速的频率t〉200次／min。24例（75％）患者有〉t2种形态的室速。在非接触式标测指导下对室速的起源进行了片状消融。消融的即时成功率为84，4％（27／32），15．6％（5／32）的患者经消融后室速频率明显减慢。随访9～72（28．6±16．0）个月，无一例患者发生晕厥／黑矇。术中无并发症。随访期间81．3％的患者不服药亦无室速发生，其余均获得明显改善。结论ARVC所致的室速可在非接触式标测的指引下经片状射频消融而消除或获得明显改善。本组无一例发生心脏骤停或心脏性猝死。某些患者消融后可能出现迟发效应。     

Catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia

Arrhythmogenic right ventricular dysplasia (ARVD) is a progressive, genetically determined fibro-fatty infiltrative myocardial disease with an estimated prevalence in the general population to be 1:5,000 to 1:10,000. ARVD leads to electrical instability that may predispose to life-threatening ventricular arrhythmia, heart failure, and sudden death. We reviewed the pathological substrate for ventricular arrhythmias, ECG findings and treatment modalities in ARVD. Importantly, novel techniques such as electroanatomic and voltage mapping has greatly improved the identification of the scared substrate in the settings of ARVD and have improved safety and efficacy of VT ablation procedures associated with this entity.     

室性心动过速的基质标测与消融

目的 探讨使用Carto三维系统标测致心律失常性右心室心肌病(ARVD/C)室性心律失常的基质来指导导管消融的安全性和有效性.方法 自2007年7月至2008年4月,北京大学第一医院心内科连续收治4例ARVD/C患者,年龄28～53岁,男性3例,女性1例,其中1例患者有直系亲属猝死家族史,发作性室性早搏/室性心动过速(VT)病史3个月至24年.使用Carto三维系统进行电解剖电压标测,局部电压低于1.5 mV的区域判断为病变心肌,低于0.5 mV的区域为瘢痕区,结合传统的激动顺序标测、起搏标测、拖带标测和心室内碎裂电位,识别病变心肌范围和心动过速折返路径以指导消融.结果 4例患者电生理检查共诱发出7种形态的左束支阻滞形、VT,电解剖电压标测的低电压区主要位于右心室流人道的基底部和偏间隔部,在病变心肌与正常心肌交界区和/或环绕病变心肌的最早激动处做线性消融,4例患者均获消融即刻成功,无并发症.4例患者消融术后随访3个月至1年,有1例出现复发,口服胺碘酮控制,至今无晕厥和猝死.结论 ARVD/C的VT标测与消融安全可靠,应用三维系统进行电解剖电压标测与传统的心电标测方式相结合,可更精确判断ARVD/C的室性心律失常基质和有效提高消融成功率.     

Clinical outcomes of radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy

Background

Monomorphic ventricular tachycardia (VT) is rare in patients with hypertrophic cardiomyopathy (HCM), management of which is challenging. Limited data exists on the utility of catheter ablation for the treatment of VT in this population.

Objectives

We aimed to assess clinical outcomes of catheter ablation for VT in HCM patients.

Methods

A systematic search, without language restriction, using PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov was performed. The meta-analysis was performed using a meta-package for R version 4.0/RStudio version 1.2 and Freeman Tukey double arcsine method to establish the variance of raw proportions. Outcomes measured included (1) acute procedure success (defined as noninducible for clinical VT), (2) freedom from VT at follow-up, (3) mortality.

Results

This systematic review of six studies (three from the United States and three from Japan) incorporated a total of 68 drug-refractory HCM patients who underwent VT radiofrequency catheter ablation (mean age 57.6 ± 13.3 years, mean LVEF 45.8 ± 15.4%, 85% men, maximum septal wall thickness 17.4 ± 4.6 mm, and 32.3% with an apical aneurysm). Acute procedural success was achieved in 84.5% patients (95% confidence interval [CI]: 70.6%–95.2%) with 27.9% patients had recurrent VT requiring multiple ablations (median 1, IQR 1–3). During the follow-up period (18.3 ± 11.7 months), the pooled incidence of freedom from recurrent VT after index procedure was 70.2% (95% CI: 51.9%–86.2%), while after the last ablation was 82.8% (95% CI: 57%–99.2%). There were two deaths during follow-up, one from heart failure and one from SCD 0.8% (95% CI: 0%–5.8%).

Conclusion

The results of our pooled analysis demonstrated that catheter ablation for VT in HCM patients was associated with high acute procedural success, and reduced VT recurrence—findings comparable to previously published reports in other disease substrates.